FDA approves Persimmon Squibb's PD-1 mono-anti-Opdivo and CTLA-4 mono-anti-Yervoy combination, first-line treatment of non-small cell lung cancer

Bristol Myers Squibb announced that the FDA has approved a combination of its PD-1 mono-antiOpdivo (nivolumab) and CTLA-4 monoantigen Yervoy (ipilimumab) to treat patients with metastatic non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic mutationsthis approval is based on the results of the CheckMate-227 studyThe results of the first part of CheckMate -227 showed that patients treated with Opdivo and Yervoy had a higher overall survival (OS) during at least 29.3 months of follow-up compared to chemotherapy, with median sylwed sons of OS at 14.9 months and 17.1 months, respectively33 percent of patients treated with Opdivo plus Yervoy were still alive over an average of 43.1 months, compared with 22 percent in the chemotherapy groupa spokesman for the company said the cost of nine doses of Opdivo and three doses of Yervoy treatment was about $104,233Earlier this month, BMS said Opdivo's sales fell 2 percent to $1.8 billion in the first quarter, while Yervoy's sales were $396 million, up 3 percent from a year earlier